Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 206

1.

Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy.

Adams D, Ando Y, Beirão JM, Coelho T, Gertz MA, Gillmore JD, Hawkins PN, Lousada I, Suhr OB, Merlini G.

J Neurol. 2020 Jan 6. doi: 10.1007/s00415-019-09688-0. [Epub ahead of print] Review.

PMID:
31907599
2.

Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis.

Kapoor M, Foiani M, Heslegrave A, Zetterberg H, Lunn MP, Malaspina A, Gillmore JD, Rossor AM, Reilly MM.

J Peripher Nerv Syst. 2019 Dec;24(4):314-319. doi: 10.1111/jns.12350. Epub 2019 Oct 14.

PMID:
31583784
3.

A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib.

Manwani R, Cohen O, Sharpley F, Mahmood S, Sachchithanantham S, Foard D, Lachmann HJ, Quarta C, Fontana M, Gillmore JD, Whelan C, Hawkins PN, Wechalekar AD.

Blood. 2019 Dec 19;134(25):2271-2280. doi: 10.1182/blood.2019000834.

PMID:
31578202
4.

ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging.

Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, Fontana M, Gheysens O, Gillmore JD, Glaudemans AWJM, Hanna MA, Hazenberg BPC, Kristen AV, Kwong RY, Maurer MS, Merlini G, Miller EJ, Moon JC, Murthy VL, Quarta CC, Rapezzi C, Ruberg FL, Shah SJ, Slart RHJA, Verberne HJ, Bourque JM.

J Card Fail. 2019 Nov;25(11):e1-e39. doi: 10.1016/j.cardfail.2019.08.001. Epub 2019 Aug 29. No abstract available.

PMID:
31473268
5.

ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization.

Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, Fontana M, Gheysens O, Gillmore JD, Glaudemans AWJM, Hanna MA, Hazenberg BPC, Kristen AV, Kwong RY, Maurer MS, Merlini G, Miller EJ, Moon JC, Murthy VL, Quarta CC, Rapezzi C, Ruberg FL, Shah SJ, Slart RHJA, Verberne HJ, Bourque JM.

J Card Fail. 2019 Nov;25(11):854-865. doi: 10.1016/j.cardfail.2019.08.002. Epub 2019 Aug 29.

PMID:
31473267
6.

ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2-Diagnostic criteria and appropriate utilization.

Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, Fontana M, Gheysens O, Gillmore JD, Glaudemans AWJM, Hanna MA, Hazenberg BPC, Kristen AV, Kwong RY, Maurer MS, Merlini G, Miller EJ, Moon JC, Murthy VL, Quarta CC, Rapezzi C, Ruberg FL, Shah SJ, Slart RHJA, Verberne HJ, Bourque JM.

J Nucl Cardiol. 2019 Aug 29. doi: 10.1007/s12350-019-01761-5. [Epub ahead of print]

PMID:
31468377
7.

ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging.

Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, Fontana M, Gheysens O, Gillmore JD, Glaudemans AWJM, Hanna MA, Hazenberg BPC, Kristen AV, Kwong RY, Maurer MS, Merlini G, Miller EJ, Moon JC, Murthy VL, Quarta CC, Rapezzi C, Ruberg FL, Shah SJ, Slart RHJA, Verberne HJ, Bourque JM.

J Nucl Cardiol. 2019 Dec;26(6):2065-2123. doi: 10.1007/s12350-019-01760-6. No abstract available.

PMID:
31468376
8.

A 24-year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom.

Sharpley FA, Petrie A, Mahmood S, Sachchithanantham S, Lachmann HJ, Gillmore JD, Whelan CJ, Fontana M, Martinez-Naharro A, Quarta C, Hawkins PN, Wechalekar AD.

Br J Haematol. 2019 Dec;187(5):642-652. doi: 10.1111/bjh.16143. Epub 2019 Aug 13.

PMID:
31410841
9.

Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria.

Sharpley FA, Fontana M, Martinez-Naharro A, Manwani R, Mahmood S, Sachchithanantham S, Lachmann HJ, Gillmore JD, Whelan CJ, Hawkins PN, Wechalekar AD.

Haematologica. 2019 Aug 8. pii: haematol.2019.217695. doi: 10.3324/haematol.2019.217695. [Epub ahead of print]

10.

Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy.

Manwani R, Mahmood S, Sachchithanantham S, Lachmann HJ, Gillmore JD, Yong K, Rabin N, Popat R, Kyriakou C, Worthington S, Sharpley F, Smith M, Shah R, Cheesman S, Hawkins PN, Wechalekar AD.

Br J Haematol. 2019 Dec;187(5):638-641. doi: 10.1111/bjh.16122. Epub 2019 Aug 6.

PMID:
31388995
11.

Proteomic Analysis for the Diagnosis of Fibrinogen Aα-chain Amyloidosis.

Taylor GW, Gilbertson JA, Sayed R, Blanco A, Rendell NB, Rowczenio D, Rezk T, Mangione PP, Canetti D, Bass P, Hawkins PN, Gillmore JD.

Kidney Int Rep. 2019 Apr 15;4(7):977-986. doi: 10.1016/j.ekir.2019.04.007. eCollection 2019 Jul.

12.

Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis.

Baggiano A, Boldrini M, Martinez-Naharro A, Kotecha T, Petrie A, Rezk T, Gritti M, Quarta C, Knight DS, Wechalekar AD, Lachmann HJ, Perlini S, Pontone G, Moon JC, Kellman P, Gillmore JD, Hawkins PN, Fontana M.

JACC Cardiovasc Imaging. 2020 Jan;13(1 Pt 1):69-80. doi: 10.1016/j.jcmg.2019.03.026. Epub 2019 Jun 12.

PMID:
31202744
13.

The UK National Amyloidosis Centre.

Hawkins PN, Fontana M, Gillmore JD.

Eur Heart J. 2019 Jun 1;40(21):1661-1664. doi: 10.1093/eurheartj/ehz346. No abstract available.

PMID:
31152551
14.

Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers.

Rezk T, Lachmann HJ, Fontana M, Naharro AM, Sachchithanantham S, Mahmood S, Petrie A, Whelan CJ, Pinney JH, Foard D, Lane T, Youngstein T, Wechalekar AD, Hawkins PN, Gillmore JD.

Br J Haematol. 2019 Aug;186(3):460-470. doi: 10.1111/bjh.15955. Epub 2019 May 24.

PMID:
31124579
15.

Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis.

Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, Rowczenio DM, Gilbertson JA, Hutt DF, Rezk T, Strehina SG, Caringal-Galima J, Manwani R, Sharpley FA, Wechalekar AD, Lachmann HJ, Mahmood S, Sachchithanantham S, Drage EPS, Jenner HD, McDonald R, Bertolli O, Calleja A, Hawkins PN, Gillmore JD.

Circulation. 2019 Jul 2;140(1):16-26. doi: 10.1161/CIRCULATIONAHA.118.038169. Epub 2019 May 21. Erratum in: Circulation. 2019 Jul 30;140(5):e185.

PMID:
31109193
16.

High Prevalence of Intracardiac Thrombi in Cardiac Amyloidosis.

Martinez-Naharro A, Gonzalez-Lopez E, Corovic A, Mirelis JG, Baksi AJ, Moon JC, Garcia-Pavia P, Gillmore JD, Hawkins PN, Fontana M.

J Am Coll Cardiol. 2019 Apr 9;73(13):1733-1734. doi: 10.1016/j.jacc.2019.01.035. No abstract available.

PMID:
30947929
17.

High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial.

Hutchison CA, Cockwell P, Moroz V, Bradwell AR, Fifer L, Gillmore JD, Jesky MD, Storr M, Wessels J, Winearls CG, Weisel K, Heyne N, Cook M.

Lancet Haematol. 2019 Apr;6(4):e217-e228. doi: 10.1016/S2352-3026(19)30014-6. Epub 2019 Mar 11.

PMID:
30872075
18.

Spinal Stenosis in Familial Transthyretin Amyloidosis.

Carr AS, Shah S, Choi D, Blake J, Phadke R, Gilbertson J, Whelan CJ, Wechalekar AD, Gillmore JD, Hawkins PN, Reilly MM.

J Neuromuscul Dis. 2019;6(2):267-270. doi: 10.3233/JND-180348.

PMID:
30856118
19.

The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis.

Rezk T, Gilbertson JA, Mangione PP, Rowczenio D, Rendell NB, Canetti D, Lachmann HJ, Wechalekar AD, Bass P, Hawkins PN, Bellotti V, Taylor GW, Gillmore JD.

J Pathol Clin Res. 2019 Jul;5(3):145-153. doi: 10.1002/cjp2.126. Epub 2019 Apr 2.

20.

Acute changes in cardiac structural and tissue characterisation parameters following haemodialysis measured using cardiovascular magnetic resonance.

Kotecha T, Martinez-Naharro A, Yoowannakul S, Lambe T, Rezk T, Knight DS, Hawkins PN, Moon JC, Muthurangu V, Kellman P, Rakhit RD, Gillmore JD, Jeetley P, Davenport A, Fontana M.

Sci Rep. 2019 Feb 4;9(1):1388. doi: 10.1038/s41598-018-37845-4.

21.

A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis.

Sharpley FA, Manwani R, Mahmood S, Sachchithanantham S, Lachmann HJ, Gillmore JD, Whelan CJ, Fontana M, Hawkins PN, Wechalekar AD.

Blood Cancer J. 2019 Feb 4;9(2):16. doi: 10.1038/s41408-019-0180-1. No abstract available.

22.

Hereditary systemic amyloidosis caused by K19T apolipoprotein C-II variant.

Liapis K, Panagopoulou P, Charitaki E, Rowczenio D, Gilbertson J, Papathoma A, Kostopoulou M, Dimopoulos MA, Gillmore JD, Kastritis E.

Amyloid. 2019 Mar;26(1):52-53. doi: 10.1080/13506129.2018.1562442. Epub 2019 Jan 26. No abstract available.

PMID:
30686043
23.

A pilot study demonstrating cardiac uptake with 18F-florbetapir PET in AL amyloidosis patients with cardiac involvement.

Manwani R, Page J, Lane T, Burniston M, Skillen A, Lachmann HJ, Gillmore JD, Fontana M, Whelan C, Hawkins PN, Wagner T, Wechalekar AD.

Amyloid. 2018 Dec;25(4):247-252. doi: 10.1080/13506129.2018.1552852. Epub 2019 Jan 19.

PMID:
30661419
24.

Publisher Correction: The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.

Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D'Agati VD, Dispenzieri A, Fervenza FC, Fermand JP, Gibbs S, Gillmore JD, Herrera GA, Jaccard A, Jevremovic D, Kastritis E, Kukreti V, Kyle RA, Lachmann HJ, Larsen CP, Ludwig H, Markowitz GS, Merlini G, Mollee P, Picken MM, Rajkumar VS, Royal V, Sanders PW, Sethi S, Venner CP, Voorhees PM, Wechalekar AD, Weiss BM, Nasr SH.

Nat Rev Nephrol. 2019 Feb;15(2):121. doi: 10.1038/s41581-018-0102-7.

PMID:
30568288
25.

The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.

Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D'Agati VD, Dispenzieri A, Fervenza FC, Fermand JP, Gibbs S, Gillmore JD, Herrera GA, Jaccard A, Jevremovic D, Kastritis E, Kukreti V, Kyle RA, Lachmann HJ, Larsen CP, Ludwig H, Markowitz GS, Merlini G, Mollee P, Picken MM, Rajkumar VS, Royal V, Sanders PW, Sethi S, Venner CP, Voorhees PM, Wechalekar AD, Weiss BM, Nasr SH.

Nat Rev Nephrol. 2019 Jan;15(1):45-59. doi: 10.1038/s41581-018-0077-4. Erratum in: Nat Rev Nephrol. 2019 Feb;15(2):121.

PMID:
30510265
26.

Quantitation of 99mTc-DPD uptake in patients with transthyretin-related cardiac amyloidosis.

Ross JC, Hutt DF, Burniston M, Page J, Steeden JA, Gillmore JD, Wechalekar AD, Hawkins PN, Fontana M.

Amyloid. 2018 Sep;25(3):203-210. doi: 10.1080/13506129.2018.1520087.

PMID:
30486686
27.

Bioimpedance vector analysis for the detection of extracellular volume overload and sarcopenia in systemic AL amyloidosis.

Rezk T, Davenport A, Gan JJ, Lachmann HJ, Fontana M, Martinez-Naharro A, Sachchithanantham S, Guillotte C, Mahmood S, Petrie A, Whelan CJ, Pinney JH, Foard D, Lane T, Youngstein T, Wechalekar AD, Hawkins PN, Gillmore JD.

Br J Haematol. 2019 Jun;185(5):977-980. doi: 10.1111/bjh.15675. Epub 2018 Nov 18. No abstract available.

PMID:
30450572
28.

Analysis of the TTR gene in the investigation of amyloidosis: A 25-year single UK center experience.

Rowczenio D, Quarta CC, Fontana M, Whelan CJ, Martinez-Naharro A, Trojer H, Baginska A, Ferguson SM, Gilbertson J, Rezk T, Sachchithanantham S, Mahmood S, Manwani R, Sharpley F, Wechalekar AD, Hawkins PN, Gillmore JD, Lachmann HJ.

Hum Mutat. 2019 Jan;40(1):90-96. doi: 10.1002/humu.23669. Epub 2018 Nov 1.

PMID:
30328212
29.

Reply: Amyloidosis in the Era of Mass Spectrometry-Based Proteomics.

Kotecha T, Martinez-Naharro A, Gillmore JD, Hawkins PN, Fontana M.

J Am Coll Cardiol. 2018 Oct 9;72(15):1881. doi: 10.1016/j.jacc.2018.08.1036. No abstract available.

30.

Plasminogen activation triggers transthyretin amyloidogenesis in vitro.

Mangione PP, Verona G, Corazza A, Marcoux J, Canetti D, Giorgetti S, Raimondi S, Stoppini M, Esposito M, Relini A, Canale C, Valli M, Marchese L, Faravelli G, Obici L, Hawkins PN, Taylor GW, Gillmore JD, Pepys MB, Bellotti V.

J Biol Chem. 2018 Sep 14;293(37):14192-14199. doi: 10.1074/jbc.RA118.003990. Epub 2018 Jul 17.

31.

Myocardial Edema and Prognosis in Amyloidosis.

Kotecha T, Martinez-Naharro A, Treibel TA, Francis R, Nordin S, Abdel-Gadir A, Knight DS, Zumbo G, Rosmini S, Maestrini V, Bulluck H, Rakhit RD, Wechalekar AD, Gilbertson J, Sheppard MN, Kellman P, Gillmore JD, Moon JC, Hawkins PN, Fontana M.

J Am Coll Cardiol. 2018 Jun 26;71(25):2919-2931. doi: 10.1016/j.jacc.2018.03.536.

32.

Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine.

Manwani R, Sachchithanantham S, Mahmood S, Foard D, Sharpley F, Rezk T, Lane T, Quarta C, Fontana M, Lachmann HJ, Gillmore JD, Whelan C, Hawkins PN, Wechalekar AD.

Blood. 2018 Aug 16;132(7):761-764. doi: 10.1182/blood-2018-04-846493. Epub 2018 Jun 20. No abstract available.

PMID:
29925500
33.

Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1.

Borthwick NJ, Lane T, Moyo N, Crook A, Shim JM, Baines I, Wee EG, Hawkins PN, Gillmore JD, Hanke T, Pepys MB.

PLoS One. 2018 May 17;13(5):e0197299. doi: 10.1371/journal.pone.0197299. eCollection 2018.

34.

Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles.

Knight DS, Zumbo G, Barcella W, Steeden JA, Muthurangu V, Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Kotecha T, Francis R, Rezk T, Quarta CC, Whelan CJ, Lachmann HJ, Wechalekar AD, Gillmore JD, Moon JC, Hawkins PN, Fontana M.

JACC Cardiovasc Imaging. 2019 May;12(5):823-833. doi: 10.1016/j.jcmg.2018.02.016. Epub 2018 Apr 18.

PMID:
29680336
35.

Native T1 and Extracellular Volume in Transthyretin Amyloidosis.

Martinez-Naharro A, Kotecha T, Norrington K, Boldrini M, Rezk T, Quarta C, Treibel TA, Whelan CJ, Knight DS, Kellman P, Ruberg FL, Gillmore JD, Moon JC, Hawkins PN, Fontana M.

JACC Cardiovasc Imaging. 2019 May;12(5):810-819. doi: 10.1016/j.jcmg.2018.02.006. Epub 2018 Mar 14.

PMID:
29550324
36.

Diagnosis, pathogenesis and outcome in leucocyte chemotactic factor 2 (ALECT2) amyloidosis.

Rezk T, Gilbertson JA, Rowczenio D, Bass P, Lachmann HJ, Wechalekar AD, Fontana M, Mahmood S, Sachchithanantham S, Whelan CJ, Wong J, Rendell N, Taylor GW, Hawkins PN, Gillmore JD.

Nephrol Dial Transplant. 2018 Feb 1;33(2):241-247. doi: 10.1093/ndt/gfw375.

PMID:
29401357
37.

Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis.

Manwani R, Foard D, Mahmood S, Sachchithanantham S, Lane T, Quarta C, Youngstein T, Rezk T, Lachmann HJ, Gillmore JD, Fontana M, Whelan C, Hawkins PN, Wechalekar A.

Haematologica. 2018 Apr;103(4):e165-e168. doi: 10.3324/haematol.2017.178095. Epub 2018 Jan 5. No abstract available.

38.

Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis.

Richards DB, Cookson LM, Barton SV, Liefaard L, Lane T, Hutt DF, Ritter JM, Fontana M, Moon JC, Gillmore JD, Wechalekar A, Hawkins PN, Pepys MB.

Sci Transl Med. 2018 Jan 3;10(422). pii: eaan3128. doi: 10.1126/scitranslmed.aan3128.

PMID:
29298867
39.

Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome.

Rowczenio DM, Pathak S, Arostegui JI, Mensa-Vilaro A, Omoyinmi E, Brogan P, Lipsker D, Scambler T, Owen R, Trojer H, Baginska A, Gillmore JD, Wechalekar AD, Lane T, Williams R, Youngstein T, Hawkins PN, Savic S, Lachmann HJ.

Blood. 2018 Mar 1;131(9):974-981. doi: 10.1182/blood-2017-10-810366. Epub 2017 Dec 28.

40.

Extracellular volume with bolus-only technique in amyloidosis patients: Diagnostic accuracy, correlation with other clinical cardiac measures, and ability to track changes in amyloid load over time.

Zumbo G, Barton SV, Thompson D, Sun M, Abdel-Gadir A, Treibel TA, Knight D, Martinez-Naharro A, Thirusha L, Gillmore JD, Moon JC, Hawkins PN, Fontana M.

J Magn Reson Imaging. 2018 Jun;47(6):1677-1684. doi: 10.1002/jmri.25907. Epub 2017 Nov 21.

PMID:
29159946
41.

Renal Amyloidosis Associated With 5 Novel Variants in the Fibrinogen A Alpha Chain Protein.

Rowczenio D, Stensland M, de Souza GA, Strøm EH, Gilbertson JA, Taylor G, Rendell N, Minogue S, Efebera YA, Lachmann HJ, Wechalekar AD, Hawkins PN, Heimdal KR, Selvig K, Lægreid IK, Demoulin N, Aydin S, Gillmore JD, Wien TN.

Kidney Int Rep. 2016 Nov 19;2(3):461-469. doi: 10.1016/j.ekir.2016.11.005. eCollection 2017 May.

42.

A new staging system for cardiac transthyretin amyloidosis.

Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, Quarta CC, Rezk T, Whelan CJ, Gonzalez-Lopez E, Lane T, Gilbertson JA, Rowczenio D, Petrie A, Hawkins PN.

Eur Heart J. 2018 Aug 7;39(30):2799-2806. doi: 10.1093/eurheartj/ehx589.

PMID:
29048471
43.

Misidentification of transthyretin and immunoglobulin variants by proteomics due to methyl lysine formation in formalin-fixed paraffin-embedded amyloid tissue.

Canetti D, Rendell NB, Di Vagno L, Gilbertson JA, Rowczenio D, Rezk T, Gillmore JD, Hawkins PN, Verona G, Mangione PP, Giorgetti S, Mauri P, Motta S, De Palma A, Bellotti V, Taylor GW.

Amyloid. 2017 Dec;24(4):233-241. doi: 10.1080/13506129.2017.1385452. Epub 2017 Oct 10.

PMID:
29016222
44.

Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis.

Sachchithanantham S, Berlanga O, Alvi A, Mahmood SA, Lachmann HJ, Gillmore JD, Hawkins PN, Harding S, Wechalekar AD.

Br J Haematol. 2017 Nov;179(4):575-585. doi: 10.1111/bjh.14908. Epub 2017 Oct 8.

PMID:
28990174
45.

Pitfalls in conducting prospective trials in stage III cardiac amyloidosis - experience from the REVEAL study.

Phillips EH, Nash S, Adedayo T, Whelan CJ, Fontana M, Mahmood S, Lachmann HJ, Gillmore JD, Smith P, Clifton-Hadley L, Hawkins PN, Wechalekar AD.

Amyloid. 2017 Dec;24(4):242-244. doi: 10.1080/13506129.2017.1385453. Epub 2017 Oct 6. No abstract available.

PMID:
28984490
46.

Safety and efficacy of empirical interleukin-1 inhibition using anakinra in AA amyloidosis of uncertain aetiology.

Lane T, Wechalekar AD, Gillmore JD, Hawkins PN, Lachmann HJ.

Amyloid. 2017 Sep;24(3):189-193. doi: 10.1080/13506129.2017.1352503. Epub 2017 Jul 26.

PMID:
28745926
47.

Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor.

Rezk T, Lachmann HJ, Fontana M, Sachchithanantham S, Mahmood S, Petrie A, Whelan CJ, Pinney JH, Foard D, Lane T, Youngstein T, Wechalekar AD, Bass P, Hawkins PN, Gillmore JD.

Kidney Int. 2017 Dec;92(6):1476-1483. doi: 10.1016/j.kint.2017.05.004. Epub 2017 Jul 18.

PMID:
28729034
48.

Magnetic Resonance in Transthyretin Cardiac Amyloidosis.

Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS, Kotecha T, Francis R, Hutt DF, Rezk T, Rosmini S, Quarta CC, Whelan CJ, Kellman P, Gillmore JD, Moon JC, Hawkins PN, Fontana M.

J Am Coll Cardiol. 2017 Jul 25;70(4):466-477. doi: 10.1016/j.jacc.2017.05.053.

49.

Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre.

Lane T, Pinney JH, Gilbertson JA, Hutt DF, Rowczenio DM, Mahmood S, Sachchithanantham S, Fontana M, Youngstein T, Quarta CC, Wechalekar AD, Gillmore JD, Hawkins PN, Lachmann HJ.

Amyloid. 2017 Sep;24(3):162-166. doi: 10.1080/13506129.2017.1342235. Epub 2017 Jul 7.

PMID:
28686088
50.

Increasing the accuracy of proteomic typing by decellularisation of amyloid tissue biopsies.

Mangione PP, Mazza G, Gilbertson JA, Rendell NB, Canetti D, Giorgetti S, Frenguelli L, Curti M, Rezk T, Raimondi S, Pepys MB, Hawkins PN, Gillmore JD, Taylor GW, Pinzani M, Bellotti V.

J Proteomics. 2017 Aug 8;165:113-118. doi: 10.1016/j.jprot.2017.06.016. Epub 2017 Jun 21.

Supplemental Content

Loading ...
Support Center